Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.metabol.2016.10.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Statins and non-alcoholic fatty liver disease: A concise review.
Biomed Pharmacother
January 2025
Laboratory of Clinical and Experimental Physiopathology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, RJ, Brazil.
Non-alcoholic fatty liver disease (NAFLD) is a common hepatic manifestation of metabolic syndrome affecting 20-30 % of the adult population worldwide. This disease, which includes simple steatosis and non-alcoholic steatohepatitis, poses a significant risk for cardiovascular and metabolic diseases. Lifestyle modifications are crucial in the treatment of NAFLD; however, patient adherence remains challenging.
View Article and Find Full Text PDFEffects of Bifidobacterium and rosuvastatin on metabolic-associated fatty liver disease via the gut-liver axis.
Lipids Health Dis
December 2024
Division of Gastroenterology, Affiliated RenHe Hospital of Three Gorges University, Yichang, 443001, China.
Background/aims: Research has indicated that treatment with rosuvastatin can improve liver pathology in metabolic-associated fatty liver disease (MAFLD) patients and that treatment with Bifidobacterium can improve MAFLD. Therefore, the effects of Bifidobacterium, rosuvastatin, and their combination on related indices in a rat model of diet-induced MAFLD need to be investigated.
Methods: Forty rats were divided into five groups: the normal diet group (N), high-fat diet (HFD) model group (M), HFD + probiotic group (P), HFD + statin group (S), and HFD + probiotic + statin group (P-S).
Statin-associated regulation of hepatic PNPLA3 in patients without known liver disease.
J Intern Med
January 2025
Division of Cardiovascular Medicine, Center for Molecular Medicine, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Background And Objectives: Statins are used for metabolic dysfunction-associated steatotic liver disease (MASLD) (NAFLD) treatment, but their role in this context is unclear. Genetic variants of patatin-like phospholipase domain containing 3 (PNPLA3) are associated with MASLD susceptibility and statin treatment efficacy. Access to liver biopsies before established MASLD is limited, and statins and PNPLA3 in early liver steatosis are thus difficult to study.
View Article and Find Full Text PDFNonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment.
Nutrients
October 2024
Division of Community and Family Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan.
Article Synopsis
- Fatty acids contribute to liver issues, and PCSK9 is known to limit the liver's uptake of LDLs, which links it to nonalcoholic fatty liver disease (NAFLD) and cardiovascular risks.
- The study examined patients with familial hypercholesterolemia (FH) who were on statin treatment, measuring their blood lipid levels, PCSK9, and liver function to explore correlations.
- Results showed a significant negative correlation between PCSK9 levels and the ALT:AST ratio, suggesting that statin therapy may influence NAFLD development in FH patients through its effect on PCSK9.
Impact of rosuvastatin on metabolic syndrome patients with moderate to severe metabolic associated fatty liver disease without overt diabetes: A randomized clinical trial.
Diabetes Metab Syndr
September 2024
Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. Electronic address:
Objective: This investigation aimed to evaluate the efficacy and safety of rosuvastatin in treating moderate to severe metabolic associated fatty liver disease (MAFLD).
Methods: This prospective, open-label, randomized study included non-diabetic participants with metabolic syndrome and intrahepatocellular lipid (IHCL) levels >10 %, as determined by proton magnetic resonance spectroscopy (H-MRS). The primary objective was the effect of a 52-week rosuvastatin treatment (10 mg/day) on IHCL content.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!